Frontlight ResearchEarly access
Spinal muscular atrophy trials in India
1 trial · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Where
- Ahmedabad
- Age
- 0 days to 42 days
- People
- 30 worldwide
- Run by
- Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00